By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompanied by periodic exacerbations. Pharmacotherapy is an important component in the general treatment of diseases of the prostate. In addition, treatment often ends in defeat due to improper therapy, omission of medications, and when the condition is alleviated, the disease is ignored.
Thus, 20-30% of patients are not satisfied with the treatment, they do not feel a decrease in the symptoms of urinary disorders and an improvement in the quality of life. This is most likely due to an incorrect assessment of lower urinary tract function in men with BPH and consequently to the choice of inappropriate treatment.
As you know, prostatitis is acute and chronic (PC), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- Chronic abacterial prostatitis: 80 to 90%, including prostatodynia, 20 to 30%.
The most common is chronic abacterial prostatitis, which should be controlled and promptly prevented exacerbations with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5α-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products derived from insects).
At the same time, in 13-30% of the effect of the use of α-blockers does not occur within 3 months after treatment; additional therapy with drugs from this group is not recommended.
When prescribing finasteride, the doctor should be prepared for the fact that the most important side effects of the drug: impotence, decreased libido, decreased ejaculation volume can lead to the patient withdrawing from the drug himself.
Treatment of BPH and prostatitis is a major urological problem that has not been fully resolved.
Frequent exacerbations of CP in the absence of indications for surgery on the prostate gland force the doctor to use additional methods in drug treatment. Often, the presence of concomitant PC aggravates the course of BPH, because the inflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine offers us new opportunities for the treatment of CP and BPH and the prevention of exacerbations.